zamtocabtagene autoleucel (MB-CART2019.1)
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Neoplasm
Conditions
B-Cell Neoplasm
Trial Timeline
Aug 4, 2025 → Dec 31, 2029
NCT ID
NCT06508931About zamtocabtagene autoleucel (MB-CART2019.1)
zamtocabtagene autoleucel (MB-CART2019.1) is a phase 2 stage product being developed by Thermo Fisher Scientific for B-Cell Neoplasm. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06508931. Target conditions include B-Cell Neoplasm.
What happened to similar drugs?
3 of 20 similar drugs in B-Cell Neoplasm were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06508931 | Phase 2 | Recruiting |
Competing Products
20 competing products in B-Cell Neoplasm